Literature DB >> 8903859

Childhood IgM nephropathy: comparison with minimal change disease.

A Al-Eisa1, J E Carter, D S Lirenman, A B Magil.   

Abstract

The distinctiveness of IgM nephropathy (IgMN) as a clinicopathologic entity is controversial. Twenty-seven children (16 males, 11 females) with IgMN as defined immunohistochemically by diffuse mesangial staining of glomeruli for IgM were compared to a group of 63 children (40 males, 23 females) with minimal change disease (MCD). While mesangial expansion was significantly greater in IgMN than in MCD (p = 0.0014), there were no significant differences between the two groups with respect to the other biopsy factors. IgMN showed a significantly higher incidence of hypertension at presentation. More than 90% of patients in both groups presented with the nephrotic syndrome which in most initially responded to prednisone. Frequently relapsing/steroid-dependent nephrotic syndrome was the most common indication for biopsy in both groups. Approximately 60% of patients from both groups received cytotoxic therapy. Eight percent of IgMN and 7% of MCD patients failed to respond to therapy. Relapse rates and mean dose of prednisone at relapse were very similar in both groups prior to biopsy. Relapse rates diminished significantly after treatment in the postbiopsy interval, but mean dose of prednisone at relapse did not change appreciably over time. None of the patients developed renal failure or hypertension in the follow-up period. At last visit 23% of IgMN and 27% of MCD had proteinuria. The results indicate that IgMN and MCD are indistinguishable clinically in children who are biopsied for the nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8903859     DOI: 10.1159/000188804

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  14 in total

1.  Is cyclophosphamide effective in patients with IgM-positive minimal change disease?

Authors:  Pavel Geier; Amani Roushdi; Sylva Skálová; Jennifer Vethamuthu; Gabrielle Weiler; Janusz Feber
Journal:  Pediatr Nephrol       Date:  2012-06-24       Impact factor: 3.714

2.  IgM nephropathy; time to act.

Authors:  Muhammed Mubarak
Journal:  J Nephropathol       Date:  2014-01-01

3.  Percutaneous ultrasound-guided renal biopsy in children: a single centre experience.

Authors:  N Printza; J Bosdou; A Pantzaki; M Badouraki; K Kollios; Ch Ghogha; F Papachristou
Journal:  Hippokratia       Date:  2011-07       Impact factor: 0.471

4.  IgM nephropathy in India: a single centre experience.

Authors:  Aruna V Vanikar; Kamal V Kanodia; Rashmi D Patel; Kamlesh S Suthar; Himanshu V Patel; Manoj R Gumber; Hargovind L Trivedi
Journal:  Indian J Pediatr       Date:  2012-08       Impact factor: 1.967

5.  Do C1q or IgM nephropathies predict disease severity in children with minimal change nephrotic syndrome?

Authors:  Mateja Vintar Spreitzer; Alenka Vizjak; Dušan Ferluga; Rajko B Kenda; Tanja Kersnik Levart
Journal:  Pediatr Nephrol       Date:  2013-07-13       Impact factor: 3.714

6.  Minimal change disease with IgM+ immunofluorescence: a subtype of nephrotic syndrome.

Authors:  Sarah J Swartz; Karen W Eldin; M John Hicks; Daniel I Feig
Journal:  Pediatr Nephrol       Date:  2009-02-14       Impact factor: 3.714

7.  Histopathological spectrum of childhood nephrotic syndrome in Pakistan.

Authors:  Muhammed Mubarak; Ali Lanewala; Javed Iqbal Kazi; Fazal Akhter; Atika Sher; Amir Fayyaz; Sajid Bhatti
Journal:  Clin Exp Nephrol       Date:  2009-07-28       Impact factor: 2.801

8.  Intravenous pulse cyclophosphamide--is it effective in children with steroid-resistant nephrotic syndrome?

Authors:  Hammad O Alshaya; Jaudah A Al-Maghrabi; Jameela A Kari
Journal:  Pediatr Nephrol       Date:  2003-09-17       Impact factor: 3.714

Review 9.  IgM nephropathy; can we still ignore it.

Authors:  Aruna Vanikar
Journal:  J Nephropathol       Date:  2013-04-01

Review 10.  IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis?

Authors:  R Brugnano; R Del Sordo; C Covarelli; E Gnappi; S Pasquali
Journal:  J Nephrol       Date:  2016-02-03       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.